Clinical Trials Browser

Completed × INDUSTRY × ON 01910 × Clear all

NCT01926587 2021-06-16

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

Phase 1/2 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01241500 2020-06-30

ONTIME

Phase 3 Completed

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01928537 2020-06-30

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Phase 3 Completed

Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00854646 2018-01-10

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00856791 2017-07-21

Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients

Phase 2 Completed

1 enrolled 5 charts

Neoplasms, Ovarian Neoplasms

NCT00854945 2017-06-26

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

Phase 1/2 Completed

Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01167166 2017-06-26

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Phase 1/2 Completed

LymphoidMyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT01807546 2017-06-26

Oral Rigosertib for Squamous Cell Carcinoma

Phase 2 Completed

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00861328 2017-06-23

Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT00861783 2017-06-23

Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma

Phase 1 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT01125891 2017-06-23

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors

Phase 1 Completed

Other neoplasmOther solid neoplasm

Malignant Neoplasmas

NCT01165905 2017-06-23

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT01168011 2017-06-23

Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumor

NCT01538537 2017-06-23

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Phase 1 Completed

Neoplasms

NCT01538563 2017-06-23

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Phase 1 Completed

Neoplasms

NCT02107235 2017-06-23

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

Phase 1 Completed

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT01360853 2016-08-04

ONTRAC

Phase 3 Completed

Gastrointestinal

Pancreatic Neoplasms